Skip to content

Genetic Information Assistant in Telegenetics

A Prospective, Randomized Trial to Compare Telegenetics to Counseling Via a Novel Genetic Information Assistant in High-risk Cancer Patients.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06089421
Enrollment
96
Registered
2023-10-18
Start date
2025-04-01
Completion date
2027-08-01
Last updated
2025-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gene Mutation-Related Cancer, Genetic Predisposition

Brief summary

The goal of this clinical trial is to learn about different ways cancer genetic screening can be provided to rural communities in participants at high risk for certain cancers. The main question it aims to answer is: • Does receiving pre-genetic test education with a chat bot or genetic counselor affect if the participant decides to get genetic testing? Participants will: * have a pre-test genetic counselling session with a genetic counselor or the GIA chatbot * answer questions about their cancer genetic knowledge and how they are doing * provide a saliva sample for genetic testing to test for cancer gene mutations * have their genetic testing results provided to them. * have the option to share their genetic testing results with family members Researchers will compare how many participants who had pre-genetic counseling with the chatbot received genetic testing to how many participants who had pre-genetic counseling with a genetic counselor received genetic testing.

Detailed description

High risk patients will be randomized to standard of care telegenetics with a UVA Genetic Counselor (GC) for pre-test counseling or to the novel interventional arm of pre-test counseling via Genetic Information Assistant (GIA). Participants in the study will receive their link for a telegenetics appointment or GIA link based on randomization and patients will complete pre-test genetic counseling via their assigned treatment arm. Participants will not be masked to their trial arm assignment. In the telegenetics arm, patients will be offered a video visit scheduled through Epic zoom or a phone visit in our cancer genetics clinic per standard of care. Patients randomized to the GIA arm will receive a personalized link based on their family history. At the completion of counseling, participants will be offered genetic testing. If they agree, they will be mailed a saliva kit via Invitae Genetics for panel based genetic testing via The Invitae Common Hereditary Cancers panel to analyze 47 genes associated with cancers of the breast, ovary, uterus, and gastrointestinal system, which includes the stomach, colon, rectum, small bowel, and pancreas.

Interventions

OTHERGenetic Information Assistant

Participants assigned will receive a link to Genetic Information Assistant for pre-test counseling.

OTHERTelegenetics with UVA genetic counselor

Participants assigned will have a pre-test counseling session via a telegentics visit with a genetic counselor.

Sponsors

University of Virginia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* At high risk for having a genetic pathogenic variant as assessed by a GC or physician according to the NCCN guidelines * Provision of signed and dated informed consent form. * Stated willingness to comply with all study procedures and availability for the duration of the study. * Male or female, aged 18 and over. * Subjects must have a smartphone with access to cellular and/or internet service or a computer with internet service. * Subjects must have technological competency/proficiency to use their Smartphone and/or computer in conjunction with the communication aid GIA.

Exclusion criteria

* Cannot communicate in English or Spanish. * Subjects must not have completed panel-based cancer genetic testing in the past.

Design outcomes

Primary

MeasureTime frameDescription
To assess feasibility of using a chatbot (GIA) for pre-test genetic counseling compared to standard of care GC3 monthsdichotomous measurement of whether the randomized participant completes genetic testing within three months.

Secondary

MeasureTime frameDescription
To test cancer knowledge following the pre-test genetic counseling with GIA versus GC3 monthsNational Center for Human Genome Research Knowledge scale taken at baseline and one month after genetic testing.
To assess differences of Comprehensive Score of Financial Toxicity scale6 monthsTo assess the difference in comprehensive score between one- and six-months of Comprehensive Score for Financial Toxicity (COST) survey. Scoring: 0 (Poor Financial well-being) to 48 (Better financial well-being)
To assess differences of SURE scale6 monthsTo assess the difference in comprehensive scores of the following surveys between one- and six-months of SURE scale. Scoring 0-4: Score \<4 is a positive result for decisional conflict.
To assess differences of Decisional Conflict scale6 monthsTo assess the difference in comprehensive scores of the following surveys between one- and six-months Decisional Conflict Scale. Scoring: 0 (no decisional conflict) to 100 (extremely high decisional conflict)
To assess differences of Multi-dimensional Impact of Cancer Risk Assessment (MICRA) scale6 monthsTo assess the difference in comprehensive scores of the following surveys between one- and six-months Multi-dimensional Impact of Cancer Risk Assessment (MICRA) survey

Countries

United States

Contacts

Primary ContactEvelyn Villalobos
EV4PD@uvahealth.org(434) 297-4579
Backup ContactJoseph Petruzziello
BNW4RM@uvahealth.org(434) 323-1749

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026